Global Human Microbiome Markets (2019-2030), Drugs, Companies, Therapeutics, Diagnostics, Case Studies, Executive Insights, and More

News provided by

Jan 03, 2020, 06:30 ET

DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.

The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across:

[A] type of therapy (prescription drugs, prebiotics, and probiotics)
[B] type of molecule (small molecules and biologics)
[C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn's disease, diabetes, irritable bowel syndrome, lactose intolerance, nonalcoholic steatohepatitis (NASH), ulcerative colitis, and 5+ categories)
[D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others)
[E] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)
[F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)
[G] leading drug developers
[H] leading therapeutic products

In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across:

[A] target indication (Crohn's disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis)
[B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology)
[C] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)
[D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)

In addition to other elements, the study includes:

A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.
Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.
A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.
A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.
An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.
An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.
An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.3. Overview of Gut Flora
3.4. The Microbiome and Disease
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes
3.7. Microbiome Therapeutics
3.8. The Human Microbiome Project (HMP)
3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges in the Development of Microbiome Therapeutics
3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.3. Microbiome Therapeutics: Early-Stage Pipeline
4.4. Microbiome Therapeutics: List of Drug Developers
4.5. Microbiome Therapeutics: List of Discontinued Drugs
4.6. Emerging Role of Microbiome in Gut-Brain Axis
4.7. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. 4D Pharma
5.3. Armata Pharmaceuticals
5.4. Evelo Biosciences
5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)
5.6. Seres Therapeutics
5.7. Vedanta Biosciences

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Overview of Microbiome Diagnostic Tests
6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products
6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers
6.5. Profiles of Prominent Diagnostic Developers
6.6. Overview of Microbiome Screening / Profiling Tests

7. FECAL MICROBIOTA THERAPY (FMT)
7.1. Chapter Overview
7.2. Introduction to FMT
7.3. Historical Overview
7.4. FMT: Procedure and Clinical Relevance
7.5. Regulatory Guidelines Related to FMT
7.6. Insurance Coverage for FMT
7.7. FMT: Competitive Landscape
7.8. Clinical Trial Analysis (Non-Industry Sponsored)
7.9. Stool Banks

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.6. Concluding Remarks

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Initiatives of Big Pharmaceutical Players
9.4. Benchmark Analysis of Big Pharmaceutical Players

10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Benchmark Analysis of Start-ups

11. KEY THERAPEUTIC AREAS
11.1. Chapter Overview
11.2. Metabolic Disorders
11.3. Digestive and Gastrointestinal Disorders
11.4. Oncological Indications
11.5. Dermatological Disorders
11.6. Infectious Diseases

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS
13.1. Chapter Overview
13.2. Manufacturing Microbiome Therapeutics
13.3. Microbiome Therapeutics-related R&D
13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS
14.1. Chapter Overview
14.2. Introduction to Big Data
14.3. Internet of Things
14.4. Growing Interest in Big Data: Google Trends Analysis
14.5. Key Application Areas
14.6. Big Data in Microbiome Research
14.7. Big Data Services for Microbiome Research: List of Companies
14.8. Big Data Services for Microbiome Research: Profiles of Key Players

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology
15.4. Overall Microbiome Therapeutics Market, 2019-2030
15.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3 Forecast Methodology
16.4. Overall Microbiome Diagnostics Market, 2019-2030
16.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030
16.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030
16.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030
16.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall FMT Market, 2019-2030
17.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES
18.1. Chapter Overview
18.2. List of Microbiome Products in Other Industries
18.3. Applications of Microbiome Based Products in Agriculture Industry
18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS
20.1 Chapter Overview
20.2. Rebiotix
20.3. S-Biomedic
20.4. Whole Biome
20.5. Siolta Therapeutics
20.6. OpenBiome
20.7 Assembly Biosciences
20.8. List Biological Laboratories
20.9. Metabiomics
20.10. MicroBiome Therapeutics
20.11. Universal Stabilization Technologies
20.12. BiomX
20.13. Da Volterra
20.14. Chung Mei Pharmaceutical
20.15. Pacific Northwest National Laboratories

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

16S Technologies
4D Pharma
5QBD-Biotech
Aalborg University Hospital
Aarhus University
AB-Biotics
Abbott Laboratories
AbbVie
Abraxis BioScience
Academic Medical Centre (Amsterdam UMC)
ActoBio Therapeutics
Adapsyn Bioscience
Adare Pharmaceuticals
AdvancingBio
AEProbio
Aetna
AgBiome
Ajuvis Labsd
Alaven Pharmaceutical
Aleris-Hamlet Hospital
Alimentary Health (Part of PrecisionBiotics Group)
Alimentary Pharmabiotic Centre Microbiome Institute, University College Cork (UCC)
Allergan
Allergy Therapeutics
Altis Biosystems
Amabiotics
Amazon
American College of Gastroenterology
Ample
AmpliPhi Biosciences
Amrita Therapeutics
Anavex Life Sciences
AnimalBiome
ANIZOME
AOBiome Therapeutics
Ardigen
Arena Pharmaceuticals
Arizona State University
Armata Pharmaceuticals
Artizan Biosciences
ARTPred
Ascus Biosciences
Asia Microbiota Bank
AsiaBiome (formely known as Civet Biosciences)
Assaf Harofeh Medical Center
Assembly Biosciences
APHM (Public Assistance - Marseille Hospitals)
APHP (Public Assistance - Paris Hospitals)
Astarte Medical
Astel Medica
AstraZeneca
Atlas Biomed
Autonomous University of Nuevo Len
Aventis Pharma
AvidBiotics
Axcan Pharma
Axial Biotherapeutics
Azitra
Bactana
Bayer
Baylor College of Medicine
Becton Dickinson
Beiersdorf
Beth Israel Deaconess Medical Center
Bio Farma
Biocartis
Biocodex
BioControl (Acquired by Merck)
BioGaia
Biogen
Biohit Healthcare
BIOHM Health
Bio-K Plus International
Biom Pharmaceuticals
BioMathematica
BiomCare
Bio-Me
Biome Makers
Biome360
BiomeBliss
Biomecite Diagnostics
BiomeSense
Biomica (subsidiary of Evogene)
Biomillenia
BiomX
BioRankings
Biorasi
biose
Biotagenics
Blis Probiotics
Blue Biology
Blue Turtle Bio
Boehringer Ingelheim
BoobyBiome
Boston Children's Hospital
Boston Medical Center
Brigham and Women's Hospital
Bristol-Myers Squibb
BugSpeak
Caelus Health
California Institute of Technology (Caltech)
Campus Bio-Medico University
Canadian Association of Gastroenterology
Canadian Institutes of Health Research
Capsugel
Captozyme
Carbiotix
CARB-X
Careggi University Hospital
Case Comprehensive Cancer Center
Catholic University of the Sacred Heart
Cedars-Sinai Medical Center
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology
Center of Food and Fermentation Technologies
Centers for Disease Control and Prevention
CHAIN Biotechnology
Charles River Laboratories
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
Children's Mercy Hospital Kansas City
Chr. Hansen
Chugai Pharmaceutical
Chung Mei Pharmaceutical
ChunLab
Cigna
CIPAC Healthcare
Clasado BioSciences
ClearB Therapeutics
Clinical Investigation Center for Innovative Technology Network
Clinical Microbiomics
ClostraBio
Cobra Biologics
Commense (a subsidiary of PureTech Health)
Concentric Ag
Cook MyoSite
CoreBiome
Cornell University
CosmosID
Covaris
CRB-HUEP
Crohn's & Colitis Foundation
CRS Bio
Cykinso
Dairy & Food Culture Technologies
Dakota BioTech
Danisco
Da Volterra
Dayanand Medical College & Hospital
DayTwo
DermBiont
Diagnostic Solutions Laboratory
Diversigen
DNA Genotek
Duke University
DuPont
Eagle Genomics
Eat Troo
Eatrics
Edico Genome (Acquired by Illumina)
EirGenix
Eli Lilly
ELiE Health Solutions
Embion Technologies
EmblemHealth
Emory University
Emulate
Englewood Health
Enterin
EnteroBiotix
Enterome Bioscience
EpiBiome (Acquired by Locus Biosciences)
Esse Skincare
European Commission
European Society of Clinical Microbiology and Infectious Diseases
Evelo Biosciences
Evolve BioSystems
Evotec
EXDEN
Exeliom Biosciences (formerly known as Nextbiotix)
EzBioCloud
Fecal Microbiota Transplantation Workgroup
Federal Research and Clinical Center of Physical-Chemical Medicine
FermBiotics
Ferring Pharmaceuticals
Finch Therapeutics
First Affiliated Hospital of Chengdu Medical College
Flora Medicine
Floragraph
First Affiliated Hospital of Nanchang University
Fortify
Foundation of Hope
Fourth Military Medical University
Frontier Science & Technology Research Foundation
FUJIFILM Diosynth Biotechnologies
Fuzhou General Hospital
G.D Searle
Galderma
Galline
GALT
Genetic Analysis
Institute of Molecular Genetics Academy of Sciences Czech Republic
GENEWIZ
Genome and Company
Genova Diagnostics
Genten Therapeutics
German Federal Ministry of Education and Research
Ghent University
GI Innovation
Ginkgo Bioworks
Global Cosmetics
GNUbiotics Sciences
GoodBelly
GoodGut
Groken Bioscience
GlaxoSmithKline
GT Biologics
Guangzhou First People's Hospital
Glhane Institute of Health Sciences
Gusto Global
Hadassah Medical Center
Hamilton Health Sciences
Harvest Capital Strategies
Haukeland University Hospital
Health Net
HealthPartners
University of Helsinki
Hoechst Marion Roussel
Holobiome
Hospital District of Helsinki and Uusimaa
Hospital for Sick Children
Hospital Ramn y Cajal
Hudson Institute of Medical Research
Human Longevity
Hunter Holmes McGuire Veterans Administration Medical Center
Hvidovre Hospital
Hy Laboratories
Hyggut
IBM
Icahn School of Medicine at Mount Sinai
iCarbonX
Igen Biolab Group
ImClone Systems
ImmuneBiotech
Immunex
Immuron
Indiana University
Indigo Therapeutics
Inserm
Institut Allergosan
Institut national de la recherche agronomique
Institute for Clinical and Experimental Medicine
The Institute of Animal Physiology
Institute of Liver and Biliary Sciences
Intralytix
Intrexon
Intuition Biosciences
Invivo Healthcare
Ipsat Therapies
Ironwood Pharmaceuticals
IS-Diagnostics
Island Health
Isohelix
ISOThrive
Ixcela
Ixion Biotechnology
J. Craig Venter Institute
Janssen Biotech
Jena University Hospital
Jinling Hospital
John Theurer Cancer Center
Johnson & Johnson
Joint Authority for Pijt-Hme Social and Health Care
Juno Bio
Kaleido Biosciences
Kallyope
Karolinska Institutet
Kelsey Research Foundation
Keystone Bio
King's College London
Kingston Health Sciences Centre
Kintai Therapeutics
KNOMICS MICROBIOTA
Kobiolabs
La Trobe University
Laboratorio Cobas
Lactobio
Lallemand Health Solutions
Lavie Bio
Lawrence Berkeley National Laboratory
Lawson Health Research Institute
Leadiant Biosciences
Leiden University
Lesaffre Human Care
Levanger Hospital
List Biological Laboratories
LNC Therapeutics
Locus Biosciences
London Health Sciences Centre
Lonza
Lovisenberg Diakonale Hospital
LUCA Biologics
Luina Bio
Luxia Scientific
M.D. Anderson Cancer Center
MaaT Pharma
Madison University
Maiden Therapeutics
Mankind Pharma
Manufacturer Vilhelm Pedersen Foundation
Marqus de Valdecilla University Hospital
Masonic Cancer Center
Massachusetts General Hospital
Massachusetts Institute of Technology
MatriSys Bioscience
Mayo Clinic
McMaster University
MD Anderson Cancer Center
Medeva Pharmaceuticals
Medical College of Wisconsin
Medical University of Graz
Medlab
Memorial Medical Center Foundation
Memorial Sloan Kettering Cancer Center
Memorial University of Newfoundland
MemorialCare Health System
Merck
Merge Healthcare
Metabiomics
MetaboGen
Michael E. DeBakey Veterans Affairs Medical Center
Mitchell Cancer Institute
Microba
Microbiome Diagnostic Partners
Microbiome Health Research Institute
Microbiome Insights
Microbiome Research Centre
MicroBiome Therapeutics
Microbiome Therapeutics Innovation Group
MicrobiomeDx
Microbiotica
Microinventa
Microsoft
Microviable Therapeutics
Millennium Pharmaceuticals
Miomics
Miyarisan Pharmaceutical
Modena University Hospital
Molzym
Monash University
Montefiore Medical Center
Moon Biotech
Mount Sinai Hospital
mybacs
MyBiotics
MyMicroZoo
NAFLD Research Center, University of California San Diego School of Medicine
Naked Biome
Nantes University Hospital
National Cancer Institute (NCI)
The National Institute for Health and Care Excellence (NICE)
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute for Health and Medical Research (INSERM)
National Institutes of Health (NIH)
National Jewish Health
National PKU Alliance
Nationwide Children's Hospital
Nestl Health Science
New York University
New Zealand Society of Gastroenterology
NIZO
Nordland Hospital Trust
NorthShore University HealthSystem
Norway Regional Health Authority
Norwegian University of Science and Technology
Novartis
Novo Nordisk
Novogene
Novome Biotechnologies
Nubiyota
Open Patient data Explorative Network
Odense University Hospital
Ohio State University Wexner Medical Center
Omega Biomics
One Codex
OpenBiome
OptiBiotix
Oragenics
Oralta
Orebro University
Oregon State University
Orexigen Therapeutics
Osel
OSI Pharmaceuticals
Oslo University Hospital
OxThera
Pacific Northwest National Laboratory (PNNL)
Paragon Bioservices (unit of Catalent Biologics)
Parker Institute for Cancer Immunotherapy
Vlaamse Parkinson Liga
Parkinson's Institute and Clinical Center
Peking Union Medical College Hospital
Pendulum Therapeutics (formerly known as Whole Biome)
Perrigo
Persona Biome
Pfizer
Pharmacia & Upjohn
Pharm-Olam
Phase Genomics
Phi Therapeutics
Phylagen
Pierre and Marie Curie University
Pierre Fabre
Pillar Healthcare
Postbiotics Plus
Postgraduate Institute of Medical Education and Research
PrecisionBiotics
Presutti Laboratories
Prime Discoveries
Priority Health
Probiotical
ProdermIQ
ProDigest
Prometheus Laboratories
PSI Foundation
Psoriasis Association
Psychiatric Hospital of the University of Basel
Public Health England
Public Health Ontario
Puerta de Hierro University Hospital
Qiara
Qingdao Institute of Bioenergy and Bioprocess Technology
Quadram Institute
Quay Pharma
Queen Elizabeth II Health Sciences Centre
Queen's University
Quorum Innovations
Quotient Sciences
Rambam Healthcare Campus
Rebiotix (part of Ferring Pharmaceuticals Group)
Regence BlueShield
Regeneron Pharmaceuticals
Replete Biotics
Research Foundation - Flanders
Research Institute of St Joe's Hamilton
Resilient Biotics
Resphera Biosciences
Rise Therapeutics
Ritter Pharmaceuticals
Roche
RondinX (Acquired by BiomX)
Roswell Park Comprehensive Cancer Center
Ruprecht Karl University of Heidelberg
Rush University
Sabinsa
Saint-Antoine Hospital
Salix Pharmaceuticals
Sanofi
S-Biomedic
Scaled Microbiomics
SciBac
Scioto Biosciences
Seattle Children's Hospital
Second Genome
Seed Health
Santa Maria della Misericordia Hospital
Seres Therapeutics
SFA Therapeutics
Shanghai Children's Medical Center
Shanghai General Hospital
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
Sheba Medical Center
Shoreline Biome
Sicor
Siffra Farmaceutici
Sinai Health System
Siolta Therapeutics
Sjogren's Syndrome Foundation
SkinBioTherapeutics
Snipr Biome
Solarea Bio
Soroka Medical Center
SRZ Properties
St. Justine's Hospital
Stanford Cancer Institute
Stanford University School of Medicine
Stony Brook University
Sucampo Pharmaceuticals
Sugarlogix
Sun Genomics
Symberix
Symbiota
Symbiotix Biotherapies
Syneos Health
Synergy Worldwide
Synlogic
Synthetic Biologics
Synthetic Genomics
Taiho Pharmaceutical
Takeda Pharmaceutical
TargEDys
Tel Aviv Sourasky Medical Center
Temple University
Teva Pharmaceutical
Texas Digestive Diseases Center
Texas Children's Hospital
The BioCollective
The Chinese University of Hong Kong
The Danish Rheumatism Association
The Flanders Institute for Biotechnology
The Jackson Laboratory
The Miriam Hospital
The Research Council of Norway
The Second Affiliated Hospital of Nanjing Medical University
The University of Texas Health Science Center
The University of Texas MD Anderson Cancer Center
The Weston A Price Foundation
Thryve Digital
Tongji Hospital
Toronto Invasive Bacterial Diseases Network
Tortuga Biosciences
Trayer Biotherapeutics
Triphase Pharmaceuticals
TULA Skincare
uBioDiscovery
uBiome
UCB Pharma
Ume University
Universitair Ziekenhuis Leuven
University Health Network
University Hospital Cologne
University Hospital of Limoges
University Hospital of North Norway
University of Adelaide
University of Alberta
University of British Columbia
University of Calgary
University of California
University of Chicago
University of Chieti
University of Florence
University of Maryland
University of Massachusetts
University of Melbourne
University of Miami
University of Minnesota
University of Modena and Reggio Emilia
University of New South Wales
University of North Carolina
University of North Texas
University of Oslo
University of Pennsylvania
University of Pittsburgh
University of Portsmouth
University of Southern Denmark
University of Surrey
University of Texas
University of Toronto
University of Tromso
University of Vermont
University of Wisconsin
University of Zurich
US Army Medical Research and Materiel Command
US Department of Veterans Affairs
VA Office of Research and Development
Vaiomer
Vancouver General Hospital
Varinos
Vast Biome
Vedanta Biosciences
Vertex Pharmaceuticals
Viome
Virginia Commonwealth University
Visbiome
ViThera Pharmaceuticals
Vitrilife
Vivus
WACKER (formerly known as Synco Bio)
Washington University School of Medicine
Weill Cornell Medical College of Cornell University
Wellmicro
Western Sydney Local Health District
Westmead Institute for Medical Research
Winclove Probiotics
Wolfson Medical Center
Women's College Hospital
Xbiome
Xycrobe Therapeutics
Yakult Honsha
Yonsei University
Zehna Therapeutics
ZMD Group

For more information about this report visit https://www.researchandmarkets.com/r/sakzqu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets